New York, NY -- (SBWIRE) -- 03/30/2018 -- Overview
Skin and soft tissue infections are infections involving the layers of the skin and the soft tissues beneath it. Viruses, bacteria, and fungi generally cause skin and soft tissue infections by entering the body at a spot where a cut, scrape, bite, or other wound has broken the skin. Symptoms include swelling, warmth, and redness in a distinct area of skin, abscesses, furuncles and carbuncles. Risk factors include injury to the skin, radiation therapy, accumulation of fluid (edema) due to poor circulation, heart failure, liver disease, or past surgery to remove lymph nodes, being overweight and chronic skin conditions, such as eczema.
Click here for sample report @ http://www.wiseguyreports.com/sample-request/1646777-skin-and-soft-tissue-infections-pipeline-review-h2-2017
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Skin And Soft Tissue Infections - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Skin And Soft Tissue Infections (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Skin And Soft Tissue Infections (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Skin And Soft Tissue Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 1, 3 and 1 respectively.
Major Scope of the report:
- The pipeline guide provides a snapshot of the global therapeutic landscape of Skin And Soft Tissue Infections (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Skin And Soft Tissue Infections (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Skin And Soft Tissue Infections (Dermatology) therapeutics and enlists all their major and minor projects.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Skin And Soft Tissue Infections - Overview
Skin And Soft Tissue Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Skin And Soft Tissue Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Skin And Soft Tissue Infections - Companies Involved in Therapeutics Development
Atox Bio Ltd
CorMedix Inc
Takeda Pharmaceutical Company Ltd
Valevia UK Ltd
Wockhardt Ltd
Skin And Soft Tissue Infections - Drug Profiles
ADEP-4 - Drug Profile
Product Description
.Continued
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1646777-skin-and-soft-tissue-infections-pipeline-review-h2-2017
About Wise Guy Reports
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.